| Use | CL2A-SN-38 is a drug-linker conjugate, which is formed by linking linker CL2A and toxic molecule SN-38, and can be used to prepare antibody-coupled drugs. CL2A-SN-38 showed specific anti-tumor effects against human solid tumors. SN-38 is a DNA Topoisomerase I inhibitor. CL2A is a non-cleavable PEG8-and triazo-containing PBC-peptide-mc linker. CL2A is degraded by pH sensitivity, creating a bystander effect, and binding to the cysteine residue via disulfide bonds. (CL2A-SN38 is a SN38 derivative with a peptide-linker which can easily react with antibody to form an antibody-drug conjugate (ADC). CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, givingrise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond.) |
